News Releases

Summary ToggleDose Escalation Not Required For First Generation Formulation of TXL™ EDISON, N.J. , May 04, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced it is

Summary ToggleEDISON, N.J. , May 01, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (“ContraVir”) (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced the closing on April 28, 2017 of its previously announced underwritten

Summary ToggleEDISON, N.J. , April 25, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (“ContraVir”) (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced the pricing of an underwritten public offering of common stock

Summary ToggleEDISON, N.J. , April 24, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (“ContraVir”) (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it has commenced an underwritten public offering, subject

Summary TogglePresentation Elucidating CRV431 Mode of Action Selected for EASL “Poster Tour” EDISON, N.J. , April 22, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today

Summary ToggleEDISON, NJ , April 20, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced new data demonstrating clinical antiviral activity, as well as safety and

Summary ToggleNew data to highlight TXL™ and CRV431 in Hepatitis B Virus (HBV) MEDIA ADVISORY, April 11, 2017 (GLOBE NEWSWIRE) -- WHAT: Tenofovir Exalidex (TXL™) is ContraVir’s lead drug for Hepatitis B in phase 2 clinical studies. TXL™ is a novel lipid acyclic nucleoside phosphonate that delivers high

Summary ToggleHBsAg is a key protein produced by the hepatitis B virus High levels of HBsAg are predictive of disease progression CRV431 potently inhibits the interaction between cyclophilin and HBsAg EDISON, N.J. , April 04, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc.

Summary ToggleEDISON, N.J., March 14, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at BIO-Europe Spring 2017 to be held March 20-22,

Summary ToggleChief Medical Officer to Give Oral Presentation at APASL 2017 EDISON, N.J. , Feb. 14, 2017 / PRNewswire / -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it